Insights on Drug Levels and Non-Sustained Viral Suppression With Long-Acting Cabotegravir and Rilpivirine Therapy

被引：0
|
作者：
Gutierrez, Felix [1 ,2 ,3 ]
Fernandez-Gonzalez, Marta [1 ,3 ]
Ledesma, Christian [1 ]
Losada-Echeberria, Maria [4 ]
Barrajon-Catalan, Enrique [4 ]
Masia, Mar [1 ,2 ,3 ]
机构：
[1] Hosp Gen Univ Elche, Infect Dis Unit, Elche, Spain
[2] Univ Miguel Hernandez, Dept Clin Med, Avda Univ S-N, Alicante 03202, Spain
[3] Inst Salud Carlos III, CIBERINFEC, Madrid, Spain
[4] Univ Miguel Hernandez, Inst Res Dev & Innovat Hlth Biotechnol Elche IDiBE, Elche, Spain
来源：
CLINICAL INFECTIOUS DISEASES | 2025年
关键词：
D O I：
10.1093/cid/ciae617
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Acute Hepatitis B Infection After a Switch to Long-Acting Cabotegravir and Rilpivirine
    Pintado, Claire
    Delaugerre, Constance
    Molina, Jean-Michel
    OPEN FORUM INFECTIOUS DISEASES, 2020, 7 (09):
  • [32] Virological Failure After Switch to Long-Acting Cabotegravir and Rilpivirine Injectable Therapy: An In-depth Analysis
    van Welzen, Berend J.
    Van Lelyveld, Steven F. L.
    Ter Beest, Gerjanne
    Gisolf, Jet H.
    Geerlings, Suzanne E.
    Prins, Jan M.
    Van Twillert, Gitte
    Van Nieuwkoop, Cees
    Van der Valk, Marc
    Burger, David
    Wensing, Annemarie M. J.
    CLINICAL INFECTIOUS DISEASES, 2024, 79 (01) : 189 - 195
  • [33] Cabotegravir plus rilpivirine as long-acting maintenance therapy: LATTE-2 week 48 results
    Margolis, D.
    Podzamczer, D.
    Stellbrink, H-J
    Lutz, T.
    Angel, J.
    Richmond, G.
    Clotet, B.
    Gutierrez, F.
    Sloan, L.
    Griffith, S.
    St Clair, M.
    Dorey, D.
    Ford, S.
    Mrus, J.
    Crauwels, H.
    Smith, K.
    Williams, P.
    Spreen, W.
    JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2016, 19
  • [34] COST-EFFECTIVENESS OF LONG-ACTING CABOTEGRAVIR PLUS LONG-ACTING RILPIVIRINE FOR THE TREATMENT OF HIV-1 IN TAIWAN
    Wen, Y. C.
    Ou, H. T.
    Tien, K.
    Harrison, C.
    Omonmhenle, D.
    Turner, M.
    Anderson, S. J.
    Jacob, I
    VALUE IN HEALTH, 2023, 26 (06) : S145 - S145
  • [35] Long-acting cabotegravir and rilpivirine plasma exposures in the clinical setting: The role of pharmacogenetics
    Cusato, Jessica
    Ferrara, Micol
    Antonucci, Miriam
    Goldan, Razvan
    Soloperto, Sara
    Di Perri, Giovanni
    D'avolio, Antonio
    Calcagno, Andrea
    Bonora, Stefano
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2024, 90 : 11 - 11
  • [36] WEIGHT AND LIPID CHANGES IN PHASE 3 CABOTEGRAVIR AND RILPIVIRINE LONG-ACTING TRIALS
    Patel, P.
    D'Amico, R.
    Thiagarajah, S.
    Wu, S.
    Elliot, E.
    Polli, J. W.
    Upadhyay, O.
    Van Solingen-Ristea, R.
    Orkin, C.
    Overton, E. T.
    Swindells, S.
    van Wyk, J.
    Bosse, M.
    Vannappagari, V.
    Gray, L.
    SEXUAL HEALTH, 2021, 18 (04) : VI - VI
  • [37] Management of Drug-Drug Interactions Between Long-Acting Cabotegravir and Rilpivirine and Comedications With Inducing Properties: A Modelling Study
    Bettonte, Sara
    Berton, Mattia
    Stader, Felix
    Battegay, Manuel
    Marzolini, Catia
    CLINICAL INFECTIOUS DISEASES, 2023, 76 (07) : 1225 - 1236
  • [38] Efficacy, safety and implementation outcomes of Cabotegravir plus Rilpivirine long-acting by country in the Cabotegravir and rilpivirine implementation study in European locations (CARISEL)
    Jonsson-Oldenbuettel, C.
    Ghosn, J.
    Sierra, J. Olalla
    van der Valk, M.
    Lutz, T.
    Belkhir, L.
    van Welzen, B. J.
    Hove, K.
    Ait-Khaled, M.
    DeMoor, R.
    Bontempo, G.
    Latham, C. L.
    Ngenzi, B.
    Okoli, C.
    Gutner, C. A.
    Iyer, S.
    Gill, M.
    Czarnogorski, M.
    D'Amico, R.
    van Wyk, J.
    HIV MEDICINE, 2023, 24 : 193 - 195
  • [39] Drug Exposure of Long-Acting Cabotegravir and Rilpivirine in Older People With Human Immunodeficiency Virus: A Pharmacokinetic Modeling Study
    Bettonte, Sara
    Berton, Mattia
    Stader, Felix
    Battegay, Manuel
    Marzolini, Catia
    OPEN FORUM INFECTIOUS DISEASES, 2024, 11 (04):
  • [40] Acceptability of Long-Acting Cabotegravir plus Rilpivirine in a Large, Urban, Ambulatory HIV Clinic
    Luc, Casey Morgan
    Max, Blake
    Perez, Sarah
    Herrera, Kara
    Huhn, Gregory
    Dworkin, Mark S.
    JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2024, 97 (04) : 409 - 415
12345